08:00 , Mar 2, 2015 |  BioCentury  |  Emerging Company Profile

The road to Tau

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products. Neurofibrillary tangles arise when microtubule-associated protein tau...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

Alectos Therapeutics, Merck deal

Alectos partnered with Merck to discover and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) for Alzheimer's disease (AD) and other potential disorders. The companies will jointly collaborate on discovery and preclinical development, after which Merck...
07:00 , Aug 16, 2010 |  BioCentury  |  Product Development

New tack on tau

Merck & Co. Inc. has signed on to a novel way of tackling tau, a key component of the neurofibrillary tangles in Alzheimer's disease. Last week the pharma unveiled a co-development deal with Alectos Therapeutics...
23:39 , Aug 11, 2010 |  BC Extra  |  Company News

Alectos, Merck in discovery deal for AD

Alectos Therapeutics Inc. (Burnaby, B.C.) partnered with Merck & Co. Inc. (NYSE:MRK) to discover and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) for Alzheimer's disease (AD) and other potential disorders. The companies will jointly collaborate...